Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Tibulizumab (ZB-106) (Bispecific Antibody) in Systemic Sclerosis. The expected timing is based on the latest available company guidance and may change.
TibuSURE trial. 01/12/26:- Trial enrolling. 03/05/26:- Study design poster at SSc World Congress Mar 5–7, 2026; topline results still H1 2027. 05/07/26:- TibuSURE Ph2 enrolling ~80 SSc patients on track; topline H1 2027 reiterated. 06/29/26:- TibuSURE Ph2 exceeded 80; complete enrollment in Early July. Topline data still expected H1 2027. 08/11/26:- TibuSURE Ph2 enrollment completed at 91; topline H1 2027 reiterated.
Verification
Confirm timing and program details against the company announcement or filing.